Once approved, Decapeptyl® 6-month formulation will be marketed by Debiopharm’s partners, such as Ipsen in most European Union countries. “This submission in Europe of our first 6-month-formulation ...
The approval covers a six-month sustained-release version of Decapeptyl®, an LHRH agonist. Debiopharm and its European marketing partner, Ipsen, confirmed regulatory approval of its prostate cancer ...
PARIS, Sept 25 (Reuters) - Ipsen has submitted a six-month sustained version of its prostate cancer treatment Decapeptyl for marketing approval with European health authorities, the French drugmaker ...
Ipsen (Euronext: FR0010259150; Paris: IPN) today announced the start of the filing process in Europe of the 6–month sustained release formulation of Decapeptyl ®, a luteinizing hormone releasing ...
Debiopharm (Debiopharm – www.debiopharm.com) and Ipsen (www.ipsen.com) today announced renewal of their Decapeptyl ® agreement, which extends and strengthens their strategic partnership through 2034 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback